COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER

COMPARATIVE ANALYSIS OF DIFFERENT NEOADJUVANT CHEMOTHERAPY REGIMENS FOR TRIPLE-NEGATIVE BREAST CANCER

Background. Breast cancer is a heterogeneous disease with a variety of phenotypic forms. Triple-negative breast cancer (TNBC) is one of the most aggressive subtypes characterized by high sensitivity to chemotherapy and early recurrence. Due to the lack of efficiency of standard therapeutic approache...

Full description

Bibliographic Details
Main Authors:	P. V. Krivorotko, E. K. Zhiltsova, L. P. Gigolaeva, Sh. M. Khadzhimatova, G. A. Dashyan, K. Yu. Zernov, E. S. Trufanova, А. S. Artemyeva, A. G. Kudaibergenova, V. F. Semiglazov
Format:	Article
Language:	Russian
Published:	ABV-press 2017-12-01
Series:	Опухоли женской репродуктивной системы
Subjects:	рак молочной железы трижды негативный рак молочной железы неоадъювантная полихимиотерапия полный патоморфологический ответ
Online Access:	https://ojrs.abvpress.ru/ojrs/article/view/558

Similar Items

Accuracy of core biopsy image-guided post-neoadjuvant chemotherapy breast to predict pathologic complete response
by: P. V. Krivorotko, et al.
Published: (2022-12-01)

Clinical case of torpid course of metastatic triple negative breast cancer
by: E. P. Kulikov, et al.
Published: (2022-03-01)

Neoadjuvant treatment for breast cancer
by: V. F. Semiglazov, et al.
Published: (2014-07-01)

The role of neoadjuvant chemotherapy of triple-negative breast cancer in St. Petersburg City Clinical Oncological Dispensary
by: A. G. Manikhas, et al.
Published: (2016-09-01)

Strategy of post-neoadjuvant treatment of patients with residual breast cancer
by: V. V. Semiglazov, et al.
Published: (2020-06-01)

Role of proteasome system in prognosis of breast cancer progression
by: E. E. Shashova, et al.
Published: (2018-09-01)

Efficacy and safety of cisplatin and paclitaxel (PlaTax regimen) in the neoadjuvant treatment of patients with stage II–III triple-negative breast cancer
by: O. O. Gordeeva, et al.
Published: (2020-11-01)

Results of combination treatment for triple-negative breast cancer
by: M. A. Sekundova, et al.
Published: (2014-07-01)

COMPARATIVE ANALYSIS OF THE CONTENT IN LYMPH OF HORMONES DRAWING IN PATHOGENESIS OF BREAST CANCER IN RATS WISTAR
by: A. P. Lykov, et al.
Published: (2016-02-01)

EVALUATION OF MORPHOLOGICAL AND IMMUNOHISTOCHEMICAL CHANGES OF BREAST CARCINOMAS AFTER NEOADJUVANT SYSTEMIC THERAPY
by: V. О. Bashlyk, et al.
Published: (2018-04-01)

The overview of modern approaches in treatment of triple negative breast cancer
by: A. A. Kharitonova, et al.
Published: (2020-03-01)

Time course of changes in 6-sulfatoxymelatonin excretion in patients with breast cancer after various neoadjuvant chemotherapy options
by: Yu. S. Sidorenko, et al.
Published: (2014-07-01)

ASSOCIATION OF NKT- AND ACTIVATED CD25<sup>+</sup> PERIPHERAL BLOOD LYMPHOCYTES WITH DISEASE FREE AND OVERALL SURVIVAL OF TRIPLE NEGATIVE BREAST CANCER PATIENTS
by: A. I. Chertkova, et al.
Published: (2020-12-01)

Role of positron emission tomography in predicting early tumor response to neoadjuvant chemotherapy for breast cancer
by: N. G. Chanchikova, et al.
Published: (2021-01-01)

Correlation of the value of sonoelastography strain ratio with the degree of pathological regression in patients with locally advanced breast cancer undergoing neoadjuvant chemotherapy
by: E. A. Bus’ko, et al.
Published: (2017-02-01)

Impact of various options of neoadjuvant chemotherapy on the hormonal status of patients with breast cancer
by: Yu. S. Sidorenko, et al.
Published: (2014-08-01)

NEOADJUVANT ENDOCRINE THERAPY FOR PATIENTS WITH ESTROGEN-RECEPTOR-POSITIVE BREAST CANCER
by: V. F. Semiglazov, et al.
Published: (2018-07-01)

Predoperatsionnaya (neoad\"yuvantnaya) endokrinoterapiya postmenopauzal'nykh bol'nykh rakom molochnoy zhelezy
by: V F Semiglazov, et al.
Published: (2009-09-01)

Effect of body mass index on clinical and morphological characteristics of triple negative breast cancer
by: I. B. Schepotin, et al.
Published: (2014-07-01)

The role of digital mammography, scintimammography with <sup>99m </sup>Tc-methoxyisobutylisonitrile (MIBI) and ultrasound in the diagnosis of multicentric breast cancer
by: A. V. Chernaya, et al.
Published: (2020-03-01)

Utility of dual-energy contrast-enhanced spectral mammography for the diagnosis of multicentric breast cancer
by: A. V. Chyornaya, et al.
Published: (2022-01-01)

Sovremennaya taktika ad\"yuvantnoy lekarstvennoy terapii bol'nykh operabel'nym (rannim) rakom molochnoy zhelezy
by: N I Perevodchikova
Published: (2007-06-01)

Evaluation of the scientific results of the study entitled “Opportunities for surgical treatment of patients with stage IV breast cancer” performed by Russian Society of Oncomammologists (RSOM)
by: A. A. Bozhok, et al.
Published: (2017-02-01)

The role of epidermal growth factor receptor (EGFR) in the efficacy of neoadjuvant chemotherapy in triple-negative breast cancer patients
by: N. N. Babyshkina, et al.
Published: (2020-04-01)

Magnetic resonance imaging in evaluation of efficiency of neoadjuvant chemotherapy of breast cancer
by: A. V. Komyahov, et al.
Published: (2015-12-01)

Biological rationale for a patient-specific approach in the treatment of breast cancer. Clinical value of novel biomarkers of breast cancer
by: R. M. Paltuev
Published: (2019-09-01)

X-ray and ultrasound semiotics of mucinous carcinoma of the breast
by: K. A. Lesko, et al.
Published: (2014-07-01)

PREDICTIVE VALUE OF MOLECULAR PARAMETERS IN PATIENTS WITH BASAL-LIKE TRIPL-NEGATIVE BREAST CANCER
by: О. D. Bragina, et al.
Published: (2016-02-01)

Problems in the treatment of dyshormonal breast hyperplasia: current aspects
by: E. A. Sukhareva, et al.
Published: (2014-08-01)

RELATIONSHIP OF THE IMMUNOLOGICAL PARAMETRES WITH NEOADJUVANT CHEMOTHERAPY EFFECTIVENESS IN BREAST CANCER PATIENTS
by: Y. V. Kukharev, et al.
Published: (2016-02-01)

BREAST-CONSERVING SURGERY AFTER NEOADJUVANT CHEMOTHERAPY IN BREAST CANCER PATIENTS
by: A. R. Bosieva, et al.
Published: (2021-08-01)

IMMEDIATE RESPONSE TO NEOADJUVANT CHEMOTHERAPY INCLUDING CAPECITABINE AND LONG-TERM TREATMENT OUTCOMES OF OPERABLE BREAST CANCER
by: E. M. Slonimskaya, et al.
Published: (2016-07-01)

New prospects in the use of Kadcyla® in breast cancer
by: G. A. Dashyan, et al.
Published: (2015-11-01)

Level of tumor-infiltrating lymphocytes and PD status as potential prognostic markers of survival and therapy effectiveness in triple-negative breast cancer
by: A. F. Nasretdinov, et al.
Published: (2020-06-01)

Aberrations of the number of copies (CNA) in the genome of luminal B breast tumor
by: M. K. Ibragimova, et al.
Published: (2020-10-01)

Problemy endokrinoterapii raka molochnoy zhelezy u muzhchin
by: E I Borisova, et al.
Published: (2009-03-01)

Tayverb/Tyverb (lapatinib) – pervyy dvoynoy anti-ErbB1(EGFR)i anti-ErbB2(HER2)-ingibitor v lechenii mestno-rasprostranennogo i metastaticheskogo raka molochnoy zhelezy zaregistrirovan v Rossiyskoy Federatsii
by: - -
Published: (2008-03-01)

Role of oncomarkers in diagnosis of multiple primary neoplasms of female reproductive tract
by: Yu. G. Payanidi, et al.
Published: (2014-07-01)

Experience in treating disseminated breast cancer after multimodality therapy
by: G. A. Khakimov, et al.
Published: (2014-08-01)

THE LONG-TERM RESULTS OF OCCULT BREAST CARCINOMA TREATMENT
by: T. V. Kuklenko
Published: (2017-01-01)